Immune modulation of rheumatoid arthritis

Dimitrios A. Pappas; Laura Geraldino-Pardilla; Joan M. Bathon

doi:10.1016/j.berh.2011.11.003

Immune modulation of rheumatoid arthritis

Dimitrios A. Pappas, Laura Geraldino-Pardilla, Joan M. Bathon

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

The approval - several years ago - of the first tumour necrosis factor-α (TNF-α) inhibitor for the management of rheumatoid arthritis launched a new era in the therapeutics of rheumatology. Since then an almost cataclysmic discovery of new treatment targets and corresponding biologic agents ensued. Nowadays, the rheumatologist and the rheumatologic patient have the luxury of several immune modulators available to successfully treat the majority of patients with RA or other inflammatory arthritides and conditions. In this review we focus on a discussion of the approved immune modulators/biologic agents available for the treatment of rheumatoid arthritis. We also present an overview of agents under development. For the immune modulators discussed, we describe their mechanism of action and summarise initial data and recent updates on efficacy and safety.

Original language	English (US)
Pages (from-to)	873-889
Number of pages	17
Journal	Best Practice and Research: Clinical Rheumatology
Volume	25
Issue number	6
DOIs	https://doi.org/10.1016/j.berh.2011.11.003
State	Published - Dec 2011
Externally published	Yes

Keywords

Biologic agents
Immune modulation
Rheumatoid arthritis
Treatment

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1016/j.berh.2011.11.003

Cite this

@article{b0fd9b6f45aa4dcab4ecce281597c9bc,

title = "Immune modulation of rheumatoid arthritis",

abstract = "The approval - several years ago - of the first tumour necrosis factor-α (TNF-α) inhibitor for the management of rheumatoid arthritis launched a new era in the therapeutics of rheumatology. Since then an almost cataclysmic discovery of new treatment targets and corresponding biologic agents ensued. Nowadays, the rheumatologist and the rheumatologic patient have the luxury of several immune modulators available to successfully treat the majority of patients with RA or other inflammatory arthritides and conditions. In this review we focus on a discussion of the approved immune modulators/biologic agents available for the treatment of rheumatoid arthritis. We also present an overview of agents under development. For the immune modulators discussed, we describe their mechanism of action and summarise initial data and recent updates on efficacy and safety.",

keywords = "Biologic agents, Immune modulation, Rheumatoid arthritis, Treatment",

author = "Pappas, {Dimitrios A.} and Laura Geraldino-Pardilla and Bathon, {Joan M.}",

year = "2011",

month = dec,

doi = "10.1016/j.berh.2011.11.003",

language = "English (US)",

volume = "25",

pages = "873--889",

journal = "Best Practice and Research: Clinical Rheumatology",

issn = "1521-6942",

publisher = "Bailliere Tindall Ltd",

number = "6",

}

TY - JOUR

T1 - Immune modulation of rheumatoid arthritis

AU - Pappas, Dimitrios A.

AU - Geraldino-Pardilla, Laura

AU - Bathon, Joan M.

PY - 2011/12

Y1 - 2011/12

N2 - The approval - several years ago - of the first tumour necrosis factor-α (TNF-α) inhibitor for the management of rheumatoid arthritis launched a new era in the therapeutics of rheumatology. Since then an almost cataclysmic discovery of new treatment targets and corresponding biologic agents ensued. Nowadays, the rheumatologist and the rheumatologic patient have the luxury of several immune modulators available to successfully treat the majority of patients with RA or other inflammatory arthritides and conditions. In this review we focus on a discussion of the approved immune modulators/biologic agents available for the treatment of rheumatoid arthritis. We also present an overview of agents under development. For the immune modulators discussed, we describe their mechanism of action and summarise initial data and recent updates on efficacy and safety.

AB - The approval - several years ago - of the first tumour necrosis factor-α (TNF-α) inhibitor for the management of rheumatoid arthritis launched a new era in the therapeutics of rheumatology. Since then an almost cataclysmic discovery of new treatment targets and corresponding biologic agents ensued. Nowadays, the rheumatologist and the rheumatologic patient have the luxury of several immune modulators available to successfully treat the majority of patients with RA or other inflammatory arthritides and conditions. In this review we focus on a discussion of the approved immune modulators/biologic agents available for the treatment of rheumatoid arthritis. We also present an overview of agents under development. For the immune modulators discussed, we describe their mechanism of action and summarise initial data and recent updates on efficacy and safety.

KW - Biologic agents

KW - Immune modulation

KW - Rheumatoid arthritis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84855982876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855982876&partnerID=8YFLogxK

U2 - 10.1016/j.berh.2011.11.003

DO - 10.1016/j.berh.2011.11.003

M3 - Review article

C2 - 22265267

AN - SCOPUS:84855982876

SN - 1521-6942

VL - 25

SP - 873

EP - 889

JO - Best Practice and Research: Clinical Rheumatology

JF - Best Practice and Research: Clinical Rheumatology

IS - 6

ER -

Immune modulation of rheumatoid arthritis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this